Nanosphere develops a molecular diagnostics platform for genomic and protein testing and analysis.
Nanosphere, Inc. is a nanotechnology-based healthcare company, making clinical diagnostic tests that are two to three times as sensitive as those commonly used in hospital labs today and much simpler, taking just hours rather than days or weeks to complete. The company's instruments, which use microfluidics to pull DNA and proteins from a sample, detect genetic variations in blood that make some drugs more effective in some patients than others. The key is an array of gold nanoparticles studded with chemicals that capture characteristic proteins and nucleic acids from clinical samples such as blood.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 29, 2015 | Post-IPO Debt | $4.07M | — | — | — | Detail |
Sep 19, 2013 | Post-IPO Equity | $30.20M | — | — | — | Detail |
Nov 9, 2007 | IPO | $98M | — | — | — | Detail |
May 16, 2006 | Series D | $57M | 3 | Bain Capital | — | Detail |
Jan 6, 2003 | Series C | $5M | 3 | Lurie Investment Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bain Capital | Yes | Series D |
Allen & Company | — | Series D |
Lurie Investment Fund | — | Series D |
Nextgen Partners | — | Series C |
Takata Corporation | — | Series C |